Daily Stock Analysis, OHRP, OHR Pharmaceutical Inc, priceseries

OHR Pharmaceutical Inc. Daily Stock Analysis
Stock Information
Open
4.81
Close
4.89
High
5.12
Low
4.80
Previous Close
4.93
Daily Price Gain
-0.04
YTD High
400.00
YTD High Date
Mar 17, 2014
YTD Low
1.58
YTD Low Date
Dec 31, 2018
YTD Price Change
-158.11
YTD Gain
-97.00%
52 Week High
400.00
52 Week High Date
Mar 17, 2014
52 Week Low
1.58
52 Week Low Date
Dec 31, 2018
52 Week Price Change
-158.11
52 Week Gain
-97.00%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 12. 2017
15.20
Apr 18. 2017
16.00
3 Trading Days
5.27%
Link
LONG
Aug 18. 2017
12.80
Sep 6. 2017
14.54
12 Trading Days
13.57%
Link
LONG
Nov 17. 2017
13.80
Nov 28. 2017
15.05
6 Trading Days
9.06%
Link
LONG
Jun 11. 2018
4.33
Jun 14. 2018
4.55
3 Trading Days
5.01%
Link
LONG
Aug 28. 2018
3.60
Sep 6. 2018
3.83
6 Trading Days
6.41%
Link
LONG
Oct 1. 2018
3.83
Oct 4. 2018
4.17
3 Trading Days
8.82%
Link
LONG
Jan 2. 2019
2.20
Jan 8. 2019
2.45
4 Trading Days
11.34%
Link
LONG
Mar 6. 2019
3.10
Mar 7. 2019
3.71
1 Trading Days
19.67%
Link
LONG
Apr 29. 2019
2.29
May 10. 2019
2.62
9 Trading Days
14.32%
Link
LONG
May 17. 2019
2.70
Jun 5. 2019
2.97
12 Trading Days
9.90%
Link
LONG
Jun 11. 2019
3.13
Jun 25. 2019
3.60
10 Trading Days
14.98%
Link
LONG
Jul 12. 2019
5.39
Jul 15. 2019
5.81
1 Trading Days
7.79%
Link
LONG
Jul 30. 2019
4.48
Aug 14. 2019
4.86
11 Trading Days
8.44%
Link
Company Information
Stock Symbol
OHRP
Exchange
NasdaqCM
Company URL
http://www.ohrpharmaceutical.com
Company Phone
(212) 682-8452
CEO
Ira A. Greenstein
Headquarters
New York
Business Address
800 THIRD AVENUE, 11TH FLOOR, NEW YORK, NY 10022
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001173281
About

Ohr Pharmaceutical, Inc. is a pharmaceutical company, which focuses on the development of novel pharmaceuticals for the treatment of serious and unmet medical needs. Its products include Squalamine and Trodusquemine. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY.

Description

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.